ANTITUMOR AND IMMUNE-BIOLOGICAL ACTIVITY OF A NEW METRONOMIC CHEMOTHERAPY WITH FRACTIONED CISPLATIN AND ORAL ETOPOSIDE COMBINED WITH BEVACIZUMAB (MPEBEV) FOLLOWED BY ERLOTINIB MAINTENANCE IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS

被引：0
|
作者：
Correale, Pierpaolo [1 ]
Martellucci, Ignazio [2 ]
Pastina, Pierpaolo [3 ]
Botta, Ciri-No [4 ]
Martino, Elodia [3 ]
Mazza, Daniela [3 ]
Tagliafer-Ri, Pierosandro [4 ]
Pirtoli, Luigi [3 ]
Caraglia, Michele [5 ]
机构：
[1] Siena Univ Hosp, Translat Immunooncol Ctr, Radiotherapy Unit, Siena, Italy
[2] Siena Univ Hosp, Siena, Italy
[3] Univ Siena, Unit Radiotherapy, I-53100 Siena, Italy
[4] Magna Graecia Univ Catanzaro, Med Oncol Unit, Catanzaro, Italy
[5] Univ Naples 2, Naples, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Metronomic Chemotherapy; Bevacizumab; immunebiological actvity; erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-028
引用
收藏
页码：S607 / S608
页数：2
相关论文
共 50 条
  • [31] PHASE II TRIAL OF LOW-DOSE METRONOMIC ORAL VINORELBINE COMBINED WITH BEVACIZUMAB IN PATIENTS WITH PRETREATED, ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC). PRELIMINARY RESULTS
    Kontopodis, E.
    Saridaki, Z.
    Kentepozidis, N.
    Giassas, S.
    Polyzos, A.
    Bobolaki, I.
    Christophyllakis, Ch
    Patramani, S.
    Rovithi, M.
    Georgoulias, V.
    Agelaki, S.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1244 - S1245
  • [32] CONTINUOUS INHIBITION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH ERLOTINIB ENHANCED ANTITUMOR ACTIVITY OF CHEMOTHERAPY AGAINST ERLOTINIB-RESISTANT NON SMALL CELL LUNG CANCER (NSCLC) XENOGRAFTS.
    Iwai, Toshiki
    Shirane, Masatoshi
    Moriya, Yoichiro
    Fujimoto-Ouchi, Kaori
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S579 - S579
  • [33] Vinorelbine oral (NVBO) and carboplatin (CBDCA) in chemonaive advanced non-small cell lung cancer (NSCLC): Proven efficacy of 4 cycles followed by maintenance oral chemotherapy
    Reck, Martin
    Macha, Hans-Nikol
    Del Barco, Sonia
    Cornes, Paul
    Pouget, Jean-Christophe
    Abratt, Raymond
    ANNALS OF ONCOLOGY, 2006, 17 : 226 - 226
  • [34] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
    Coudert, B.
    Ciuleanu, T.
    Park, K.
    Wu, Y. -L.
    Giaccone, G.
    Brugger, W.
    Gopalakrishna, P.
    Cappuzzo, F.
    ANNALS OF ONCOLOGY, 2012, 23 (02) : 388 - 394
  • [35] Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
    Yasuhiro Tsutani
    Yoshihiro Miyata
    Takeshi Masuda
    Kazunori Fujitaka
    Mihoko Doi
    Yoshikazu Awaya
    Shoichi Kuyama
    Soichi Kitaguchi
    Kazuhiro Ueda
    Noboru Hattori
    Morihito Okada
    BMC Cancer, 18
  • [36] Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
    Tsutani, Yasuhiro
    Miyata, Yoshihiro
    Masuda, Takeshi
    Fujitaka, Kazunori
    Doi, Mihoko
    Awaya, Yoshikazu
    Kuyama, Shoichi
    Kitaguchi, Soichi
    Ueda, Kazuhiro
    Hattori, Noboru
    Okada, Morihito
    BMC CANCER, 2018, 18
  • [37] Phase II study of metronomic chemotherapy (MC) with bevacizumab (B) in patients (Pts) with advanced (Adv) nonsquamous non-small cell lung cancer (NS-NSCLC)
    Marquette, Carrie Lee
    Grant, Stefan C.
    DeShazo, Mollie
    Reddy, Vishnu
    Cantor, Alan
    Miley, Debi
    Jerome, Mary
    Robert, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC)
    Gold, K. A.
    Lee, J. J.
    Rice, D.
    Tse, W.
    Stewart, D.
    Wistuba, I.
    Herbst, R. S.
    Lippman, S. M.
    Hong, W. K.
    Kim, E. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Interim result of a sequential administration of docetaxel followed by cisplatin-vindesine in chemotherapy naive patients with inoperable non-small cell lung cancer (NSCLC)
    Orcel, B
    Antoine, EC
    Benhammouda, A
    Vannetzel, JM
    Lenseigne, S
    Soussan-Lazard, K
    Lebras, E
    Khayat, D
    ANNALS OF ONCOLOGY, 1998, 9 : 95 - 95
  • [40] Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study
    Leon, L.
    Vazquez, S.
    Gracia, J. M.
    Lazaro, M.
    Firvida, J. L.
    Casal, J.
    Amenedo, M.
    Santome, L.
    Gallego, R.
    Anido, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345